v3.26.1
Collaboration and License Agreements and Supply Agreements - Additional Information (Details)
 1 Months Ended 12 Months Ended
Dec. 31, 2025
USD ($)
$ / shares
shares
Mar. 31, 2025
USD ($)
Jun. 30, 2024
USD ($)
May 31, 2024
USD ($)
Apr. 30, 2024
USD ($)
Nov. 30, 2023
USD ($)
Installment
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Program
PerformanceObligation
Apr. 30, 2022
USD ($)
Dec. 31, 2025
USD ($)
GoodsAndServices
$ / shares
shares
Dec. 31, 2024
USD ($)
$ / shares
shares
Dec. 31, 2022
USD ($)
shares
Mar. 31, 2024
USD ($)
$ / shares
shares
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Accounts receivable, reserve for credit losses $ 0                 $ 0 $ 0    
Common stock, shares issued | shares 8,584,309                 8,584,309 8,306,398    
Common Stock, value, issued $ 9,000                 $ 9,000 $ 8,000    
Common stock, par value | $ / shares $ 0.001                 $ 0.001 $ 0.001    
Revenue                   $ 102,484,000 $ 62,043,000    
Vaxcyte, Inc.                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
First installment milestone payment received           $ 50,000,000              
Additional milestone payment received       $ 25,000,000                  
Nonrefundable, non-creditable upfront payment receivable                       $ 10,000,000  
Common stock fair value                       $ 7,500,000  
Additional milestone payment $ 60,000,000                 60,000,000      
Shares | shares                       167,780  
Number of installments | Installment           2              
Vaxcyte, Inc. | Vaxcyte Common Stock                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Shares of common stock | shares                     667,780    
Blackstone Life Sciences                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Upfront payment received             $ 140,000,000            
Supply Agreement | Vaxcyte, Inc.                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Reimbursements expenses accruals 12,700,000                 12,700,000 $ 12,400,000    
Reimbursements expenses                   1,200,000 9,000,000    
Tasly License Agreement                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Revenue recognized from contingent payment                     5,000,000    
Maximum potential payments related to development regulatory commercialization contingent payments and milestones                 $ 350,000,000        
Reduction of research and development expenses recognized                   0 0    
Initial licensing payment due                 25,000,000        
Initial licensing payment in escrow                 $ 15,000,000        
Revenue                   104,000 6,021,000    
Tasly License Agreement | Research and Development Services                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Revenue                   0 70,000    
Tasly License Agreement | Materials supply                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Revenue                   104,000 951,000    
Astellas License and Collaboration Agreement                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Deferred revenue                     29,100,000    
Number of target programs | Program               3          
Upfront payment received                   90,000,000      
Transaction price               $ 90,000,000          
Contingent payment recognized as deferred revenue 7,500,000 $ 7,500,000                      
Constrained variable consideration 7,500,000 7,500,000                      
Nonrefundable, non-creditable upfront payment receivable                       $ 90,000,000  
Number of performance obligations | PerformanceObligation               4          
Recognition of up front payment               $ 89,100,000          
Estimated service period               4 years          
Maximum amount eligible to receive for development, regulatory and commercial milestones for each product candidate 422,500,000                 422,500,000      
Upfront payment revenue not recognized                   25,600,000      
Revenue                   45,423,000 52,868,000    
Astellas License and Collaboration Agreement | Minimum                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Total transaction price 97,500,000 90,000,000                      
Astellas License and Collaboration Agreement | Maximum                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Total transaction price 105,000,000 97,500,000                      
Astellas License and Collaboration Agreement | Research and Development Services                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Revenue                   2,459,000 5,200,000    
Astellas License and Collaboration Agreement | Materials supply                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Revenue                   7,661,000 1,479,000    
Astellas License and Collaboration Agreement | Ongoing Performance Related to Unsatisfied Performance Obligations                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Revenue 6,600,000 $ 5,700,000 $ 17,800,000             $ 31,890,000 39,900,000    
Astellas License and Collaboration Agreement | Future Services on Collaboration Joint Steering Committee ("JSC")                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Recognition of up front payment               $ 900,000          
2015 License Member | Blackstone Life Sciences | Royalty                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Upfront payment received             $ 140,000,000            
Revenue interest percentage             4.00%     4.00%      
Astellas Agreement and CFE Supply Agreement                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Deferred revenue 12,600,000                 $ 12,600,000      
Ipsen Agreement                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Number of goods and services | GoodsAndServices                   3      
Deferred revenue 0                 $ 0 $ 53,200,000    
Upfront license fee         $ 50,000,000                
Common stock, shares issued | shares                         482,738
Common Stock, value, issued                         $ 25,000,000
Common stock, par value | $ / shares                         $ 51.79
Fair market value of common stock issued         24,600,000                
Common stock premium $ 400,000       $ 400,000         400,000      
Total transaction price                   50,400,000      
Nonrefundable, non-creditable upfront payment                   $ 50,000,000